Incannex Healthcare Inc(IXHL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.68 | Insider Own | 11.6% | Shs Outstand | 12.5M | Perf Week | -4.57% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | -6.94% | Insider Trans | - | Shs Float | 11.1M | Perf Month | -16.83% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -0.51 | Inst Own | 3.97% | Short Float | 3.71% | Perf Quarter | -9.97% |
| Income | -0.02B | P/S | - | EPS this Y | -29.41% | Inst Trans | -5.04% | Short Ratio | 4.89 | Perf Half Y | -35.78% |
| Sales | 0.00B | P/B | 0.49 | EPS next 5Y | -7.39% | ROA | -41.32% | Short Interest | 0.41M | Perf YTD | -75.61% |
| Book/sh | 5.37 | P/C | 0.49 | EPS past 3/5Y | -16.41% -9.71% | ROE | -47.8% | 52W High | -82.43% ($14.91) | Perf Year | -75.07% |
| Cash/sh | 5.4 | P/FCF | - | Sales past 3/5Y | - | ROIC | -28.64% | 52W Low | 5.22% ($2.49) | Perf 3Y | -97.82% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 95.9% | Gross Margin | - | Volatility(W/M) | 4.55% 4.5% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 48.81 | EPS Q/Q | 98.8% | Profit Margin | - | RSI (14) | 28.42 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 48.81 | Sales Q/Q | - | SMA20 | -10.68% ($2.93) | Beta | 2.83 | Target Price | $18.61 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/09/02 | SMA50 | -19.01% ($3.23) | Rel Volume | 0.77 | Prev Close | $2.61 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -39.56% ($4.33) | Avg Volume(3M) | 0.08M | Price | $2.62 |
| IPO | 2022/3/2 | Option/Short | Yes/Yes | Trades | 460 | Volume | 64,578 | Change | 0.38% |
💊 Incannex Healthcare (IXHL) is an Australia-based clinical-stage biopharmaceutical company. It develops pharmaceutical candidates using cannabinoids and synthetic psilocybin, targeting chronic disease areas with significant unmet medical needs such as obstructive sleep apnea, generalized anxiety disorder, and inflammatory diseases. As a research-and-development-focused company with negligible commercial revenue, its enterprise value is driven primarily by clinical progress.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
IXHL has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -29.4% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -97.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF <0.01% It ranks #64 of 83 in the industry
Based on market cap of $33M.
ZYBT#62 Zhengye Biotechnology Holding Ltd $43M PER - 
SCYX#63 Scynexis Inc $38M PER - IXHL#64 Incannex Healthcare Inc $33M PER - 
RMTI#65 Rockwell Medical Inc $28M PER - 
CPHI#66 China Pharma Holdings Inc $27M PER - 
FAQ
What kind of company is IXHL?
IXHL belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of IXHL?
The market cap of IXHL is approximately $33M, ranking 5,044 within its sector.
What is the 52-week high and low for IXHL?
IXHL has recorded a 52-week high of $14.91 and a low of $2.49.
